SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia global en pacientes con leucemia mieloide aguda
SELLAS Life Sciences announced positive results from its Phase 3 REGAL trial showing that galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, demonstrated a statistically significant 41% reduction in risk of death in acute myeloid leukemia patients, with median overall survival of 24.0 months versus 14.7 months with standard treatment. The company plans to meet with the FDA and submit a biologics license application in the first half of 2027.